Mercer Global Advisors Inc. ADV Has $829,000 Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Mercer Global Advisors Inc. ADV grew its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 196.4% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,241 shares of the medical research company’s stock after buying an additional 1,485 shares during the quarter. Mercer Global Advisors Inc. ADV’s holdings in Charles River Laboratories International were worth $829,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Parkside Financial Bank & Trust increased its position in Charles River Laboratories International by 6.6% in the second quarter. Parkside Financial Bank & Trust now owns 402 shares of the medical research company’s stock worth $149,000 after purchasing an additional 25 shares during the period. Centerpoint Advisors LLC increased its position in Charles River Laboratories International by 60.0% in the second quarter. Centerpoint Advisors LLC now owns 80 shares of the medical research company’s stock worth $30,000 after purchasing an additional 30 shares during the period. Archer Investment Corp increased its position in Charles River Laboratories International by 13.2% in the second quarter. Archer Investment Corp now owns 257 shares of the medical research company’s stock worth $95,000 after purchasing an additional 30 shares during the period. Oppenheimer & Co. Inc. increased its position in Charles River Laboratories International by 2.4% in the second quarter. Oppenheimer & Co. Inc. now owns 1,462 shares of the medical research company’s stock worth $541,000 after purchasing an additional 34 shares during the period. Finally, Argent Trust Co increased its position in Charles River Laboratories International by 3.1% in the second quarter. Argent Trust Co now owns 1,123 shares of the medical research company’s stock worth $416,000 after purchasing an additional 34 shares during the period. Institutional investors own 93.28% of the company’s stock.

NYSE CRL opened at $455.04 on Friday. The stock has a market capitalization of $22.93 billion, a price-to-earnings ratio of 58.64, a PEG ratio of 3.07 and a beta of 1.14. The stock’s 50 day moving average price is $421.64 and its two-hundred day moving average price is $361.46. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.15 and a current ratio of 1.36. Charles River Laboratories International, Inc. has a 52 week low of $205.97 and a 52 week high of $458.27.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Tuesday, August 3rd. The medical research company reported $2.61 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.38 by $0.23. The firm had revenue of $914.61 million for the quarter, compared to analysts’ expectations of $880.72 million. Charles River Laboratories International had a return on equity of 23.59% and a net margin of 12.10%. The business’s quarterly revenue was up 34.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.58 EPS. On average, equities research analysts forecast that Charles River Laboratories International, Inc. will post 10.25 EPS for the current year.

A number of analysts recently commented on the company. Wells Fargo & Company lifted their price objective on Charles River Laboratories International from $375.00 to $470.00 and gave the stock an “overweight” rating in a research report on Thursday, August 5th. Credit Suisse Group lifted their price objective on Charles River Laboratories International from $385.00 to $420.00 and gave the stock a “neutral” rating in a research report on Thursday, August 5th. Robert W. Baird boosted their target price on Charles River Laboratories International from $410.00 to $461.00 and gave the stock an “outperform” rating in a research report on Thursday, August 5th. Zacks Investment Research lowered Charles River Laboratories International from a “buy” rating to a “hold” rating and set a $458.00 target price for the company. in a research report on Wednesday, September 15th. Finally, UBS Group boosted their target price on Charles River Laboratories International from $390.00 to $465.00 and gave the stock a “buy” rating in a research report on Tuesday, August 17th. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, Charles River Laboratories International has an average rating of “Buy” and an average target price of $400.79.

In other news, CEO James C. Foster sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 6th. The stock was sold at an average price of $401.79, for a total transaction of $4,017,900.00. Following the sale, the chief executive officer now owns 212,299 shares in the company, valued at approximately $85,299,615.21. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Birgit Girshick sold 81 shares of the company’s stock in a transaction that occurred on Monday, September 13th. The stock was sold at an average price of $442.19, for a total value of $35,817.39. Following the sale, the vice president now owns 30,025 shares in the company, valued at approximately $13,276,754.75. The disclosure for this sale can be found here. Insiders sold a total of 40,900 shares of company stock worth $16,673,320 in the last 90 days. Company insiders own 1.20% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support.

Featured Story: Correction

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.